Abbott Stock Slumps. The Nutrition Business Is a Drag on Earnings.

Market Intelligence Analysis

AI-Powered
Why This Matters

Abbott Laboratories' stock declined after the company's fourth-quarter earnings and sales fell short of Wall Street expectations, despite beating earnings per share estimates.

Market Impact

Market impact analysis based on bearish sentiment with 90% confidence.

Sentiment
Bearish
AI Confidence
90%
Time Horizon
Short Term

Article Context

Note: This is a brief excerpt for context. Click below to read the full article on the original source.

Shares of Abbott Laboratories tumbled on Thursday after the medical devices maker posted fourth-quarter earnings and sales that underwhelmed Wall Street. For the fourth quarter, Abbott reported adjusted earnings of $1.50 a share, slightly better than the $1.49 consensus among analysts tracked by FactSet The company logged roughly $11.5 billion in sales, missing the $11.8 billion analysts had forecast. The company said it expects full-year adjusted earnings in the range of $5.55 to $5.80 a share.

Continue Reading
Full article on Yahoo Finance
Read Full Article
Original article published by Yahoo Finance on January 22, 2026.
Analysis and insights provided by AnalystMarkets AI.